Back to today’s briefing

Story perspectives

Mepolizumab Halves Steroid Use in EGPA Patients

3/5/2025

36 4

Summary

Story summary

A groundbreaking study from February 2025 revealed that mepolizumab, a treatment for eosinophilic granulomatosis with polyangiitis (EGPA), has a profound impact on patient care. While 98% of the 100 participants faced adverse events, the medication halved their reliance on oral corticosteroids, slashing median doses from 10 mg to just 5 mg per day.

1 of 1

Story summary

A groundbreaking study from February 2025 revealed that mepolizumab, a treatment for eosinophilic granulomatosis with polyangiitis (EGPA), has a profound impact on patient care. While 98% of the 100 participants faced adverse events, the medication halved their reliance on oral corticosteroids, slashing median doses from 10 mg to just 5 mg per day.